{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"description":"Mean percent positive expression of EGFR and ErbB2 will be tested on pathologic tumor specimens from subjects treated with lapatinib","dispersionType":"Standard Deviation","groups":[{"description":"All participants will be asked to take Lapatinib 1250 mg po daily for a total of six months during the research study.\n\nLapatinib: All participants will be asked to take Lapatinib daily for six months during the research study.","id":"OG000","title":"Lapatinib"}],"paramType":"MEAN","populationDescription":"Of the subjects who participated in the trial, only 3 had available tumor tissue to immunostain. Therefore, results could not be reported on the other subjects.","reportingStatus":"POSTED","timeFrame":"at 6 months","title":"ErbB Receptor Expression","type":"SECONDARY","unitOfMeasure":"percent positive expression"}